TY - JOUR
T1 - Anti-neuroinflammatory potential of polyphenols by inhibiting nf-κb to halt alzheimer's disease
AU - Uddin, Md Sahab
AU - Hasana, Sharifa
AU - Ahmad, Jamil
AU - Hossain, Md Farhad
AU - Rahman, Md Mosiqur
AU - Behl, Tapan
AU - Rauf, Abdur
AU - Ahmad, Ausaf
AU - Hafeez, Abdul
AU - Perveen, Asma
AU - Ashraf, Ghulam Md
N1 - Publisher Copyright:
© 2021 Bentham Science Publishers.
PY - 2021
Y1 - 2021
N2 - Alzheimer's disease (AD) is an irrevocable chronic brain disorder featured by neuronal loss, microglial accumulation, and progressive cognitive impairment. The proper pathophysiology of this life-threatening disorder is not completely understood and no exact remedies have been found yet. Over the last few decades, research on AD has mainly highlighted pathomechanisms linked to a couple of the major pathological hallmarks, including extracellular senile plaques made of amyloid-β (Aβ) peptides, and intracellular neurofibrillary tangles (NFTs) made of tau proteins. Aβ can induce apoptosis, trigger an inflammatory response, and inhibit the synaptic plasticity of the hippocampus, which ultimately contributes to reducing cognitive functions and memory impairment. Recently, a third disease hallmark, the neuroinflammatory reaction that is mediated by cerebral innate immune cells, has become a spotlight in the current research area, assured by pre-clinical, clinical, and genetic investiga-tions. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a cytokine producer, is signifi-cantly associated with physiological inflammatory proceedings and thus shows a promising candidate for in-flammation-based AD therapy. Recent data reveal that phytochemicals, mainly polyphenol compounds, exhibit potential neuroprotective functions and these may be considered as a vital resource for discovering several drug candidates against AD. Interestingly, phytochemicals can easily interfere with the signaling pathway of NF-κB. This review represents the anti-neuroinflammatory potential of polyphenols as inhibitors of NF-κB to combat AD pathogenesis.
AB - Alzheimer's disease (AD) is an irrevocable chronic brain disorder featured by neuronal loss, microglial accumulation, and progressive cognitive impairment. The proper pathophysiology of this life-threatening disorder is not completely understood and no exact remedies have been found yet. Over the last few decades, research on AD has mainly highlighted pathomechanisms linked to a couple of the major pathological hallmarks, including extracellular senile plaques made of amyloid-β (Aβ) peptides, and intracellular neurofibrillary tangles (NFTs) made of tau proteins. Aβ can induce apoptosis, trigger an inflammatory response, and inhibit the synaptic plasticity of the hippocampus, which ultimately contributes to reducing cognitive functions and memory impairment. Recently, a third disease hallmark, the neuroinflammatory reaction that is mediated by cerebral innate immune cells, has become a spotlight in the current research area, assured by pre-clinical, clinical, and genetic investiga-tions. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a cytokine producer, is signifi-cantly associated with physiological inflammatory proceedings and thus shows a promising candidate for in-flammation-based AD therapy. Recent data reveal that phytochemicals, mainly polyphenol compounds, exhibit potential neuroprotective functions and these may be considered as a vital resource for discovering several drug candidates against AD. Interestingly, phytochemicals can easily interfere with the signaling pathway of NF-κB. This review represents the anti-neuroinflammatory potential of polyphenols as inhibitors of NF-κB to combat AD pathogenesis.
KW - Alzheimer's disease
KW - Anti-neuroinflammatory
KW - Neuroinflammation
KW - NF-κB
KW - Pathomechanisms
KW - Polyphenols
UR - http://www.scopus.com/inward/record.url?scp=85100449288&partnerID=8YFLogxK
U2 - 10.2174/1381612826666201118092422
DO - 10.2174/1381612826666201118092422
M3 - Article
C2 - 33213314
AN - SCOPUS:85100449288
SN - 1381-6128
VL - 27
SP - 402
EP - 414
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 3
ER -